New hope for bladder cancer patients who can't have standard chemo
NCT ID NCT04553939
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs (toripalimab and gemcitabine) given before surgery to 50 people with muscle-invasive bladder cancer who cannot take the standard chemotherapy drug cisplatin. The goal was to see how many patients had their tumors shrink or disappear. The approach aims to improve outcomes for this specific group.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Henan Cancer Hospital
Zhengzhou, Henan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Bag-Like device pull bladder tumors out whole?
- Can Pre-Surgery chemotherapy outsmart aggressive bladder cancer?
- Bladder cancer: a new combo aims to avoid radical surgery
- Could a simple urine test spare bladder cancer patients from chemotherapy?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Can One-Piece tumour removal improve bladder cancer outcomes?